An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction
EUROPEAN JOURNAL OF BREAST HEALTH, vol.18, no.1, pp.63-73, 2022 (Journal Indexed in ESCI)
Article / Article
Title of Journal :
EUROPEAN JOURNAL OF BREAST HEALTH
subcutaneous, trastuzumab, breast cancer, HER2, patient satisfaction, ADJUVANT CHEMOTHERAPY, FINAL ANALYSIS, SAFETY, TOLERABILITY, EXPERIENCE
Objective: This study was designed to investigate treatment satisfaction in patients and Health Care Professionals (HCP) and to evaluate the safety and tolerability of subcutaneous (SC) trastuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (eBC).